Literature DB >> 30773241

Neonatal abstinence syndrome.

Matthew Grossman1, Adam Berkwitt2.   

Abstract

Neonates exposed prenatally to opioids will often develop a collection of withdrawal signs known as neonatal abstinence syndrome (NAS). The incidence of NAS has substantially increased in recent years placing an increasing burden on the healthcare system. Traditional approaches to assessment and management have relied on symptom-based scoring tools and utilization of slowly decreasing doses of medication, though newer models of care focused on non-pharmacologic interventions and rooming-in have demonstrated promise in reducing length of hospital stay and medication usage. Data on long-term outcomes for both traditional and newer approaches to care of infants with NAS is limited and an important area of future research. This review will examine the history, incidence and pathophysiology of NAS. We will also review diagnostic screening approaches, scoring tools, differing management approaches and conclude with recommendations for continued work to improve the care of infants with NAS.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neonatal abstinence syndrome; Neonatal opioid withdrawal; Opioids; Withdrawal

Mesh:

Year:  2019        PMID: 30773241     DOI: 10.1053/j.semperi.2019.01.007

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  7 in total

1.  Polygenic risk scores and the need for pharmacotherapy in neonatal abstinence syndrome.

Authors:  Shawana Bibi; Nathan Gaddis; Eric O Johnson; Barry M Lester; Walter Kraft; Rachana Singh; Norma Terrin; Susan Adeniyi-Jones; Jonathan M Davis
Journal:  Pediatr Res       Date:  2022-08-16       Impact factor: 3.953

2.  Methadone effectively attenuates acute and long-term consequences of neonatal repetitive procedural pain in a rat model.

Authors:  Nynke J van den Hoogen; Thomas J de Geus; Jacob Patijn; Dick Tibboel; Elbert A Joosten
Journal:  Pediatr Res       Date:  2021-01-27       Impact factor: 3.756

3.  Rooming-in for Infants at Risk for Neonatal Abstinence Syndrome: Outcomes 5 Years following Its Introduction as the Standard of Care at One Hospital.

Authors:  Adam Isaiah Newman; Dane Mauer-Vakil; Helen Coo; Lynn Newton; Emily Wilkerson; Sarah McKnight; Susan B Brogly
Journal:  Am J Perinatol       Date:  2020-11-17       Impact factor: 3.079

4.  Alterations in Excitatory and Inhibitory Synaptic Development Within the Mesolimbic Dopamine Pathway in a Mouse Model of Prenatal Drug Exposure.

Authors:  Taylor Boggess; James C Williamson; Ethan B Niebergall; Hannah Sexton; Anna Mazur; Richard D Egleton; Lawrence M Grover; W Christopher Risher
Journal:  Front Pediatr       Date:  2021-12-13       Impact factor: 3.418

5.  Use of Phenobarbital to Treat Neonatal Abstinence Syndrome From Exposure to Single vs. Multiple Substances.

Authors:  Alla Kushnir; Cynthia Garretson; Maheswari Mariappan; Gary Stahl
Journal:  Front Pediatr       Date:  2022-01-31       Impact factor: 3.418

Review 6.  Neonatal Opioid Withdrawal Syndrome (NOWS): A Transgenerational Echo of the Opioid Crisis.

Authors:  Andrew E Weller; Richard C Crist; Benjamin C Reiner; Glenn A Doyle; Wade H Berrettini
Journal:  Cold Spring Harb Perspect Med       Date:  2021-03-01       Impact factor: 6.915

Review 7.  Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments.

Authors:  Fei Tang; Chee M Ng; Henrietta S Bada; Markos Leggas
Journal:  Clin Transl Sci       Date:  2021-05-01       Impact factor: 4.689

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.